Target family: Chemerin receptors (type: gpcr)
Target: chemerin receptor 1

Ligand: tethered chemerin 9 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.260000228881836 pIC50
Reference (Journal): Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids.
Published in: J Exp Med

Ligand: tethered chemerin 9 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.260000228881836 pIC50
Reference (Journal): Development of a membrane-anchored chemerin receptor agonist as a novel modulator of allergic airway inflammation and neuropathic pain.
Published in: J Biol Chem

Ligand: [3H]resolvin E1 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.95 pKd
Reference (Journal): Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1.
Published in: J Exp Med

Ligand: [3H]resolvin E1 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.95 pKd
Reference (Journal): Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation.
Published in: J Immunol

Ligand: S-26d [PMID: 37883692] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.440000057220459 pIC50
Reference (Journal): Discovery of 3-Phenyl Indazole-Based Novel Chemokine-like Receptor 1 Antagonists for the Treatment of Psoriasis.
Published in: J Med Chem

Ligand: resolvin E1 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  -

Ligand: resolvin E1 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.95 pKd
Reference (Journal): Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation.
Published in: J Immunol

Ligand: resolvin E1 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.95 pKd
Reference (Journal): Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1.
Published in: J Exp Med

Ligand: resolvin E1 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.95 pKd
Reference (Journal): Resolvins: natural agonists for resolution of pulmonary inflammation.
Published in: Prog Lipid Res

Ligand: LC52-0332 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.239999771118164 pIC50
Reference (Journal): Discovery of 3-Phenyl Indazole-Based Novel Chemokine-like Receptor 1 Antagonists for the Treatment of Psoriasis.
Published in: J Med Chem

Ligand: α-NETA (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.429999828338623 pIC50
Reference (Journal): A novel CMKLR1 small molecule antagonist suppresses CNS autoimmune inflammatory disease.
Published in: PLoS ONE

Ligand: chemerin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): The genetic design of signaling cascades to record receptor activation.
Published in: Proc Natl Acad Sci USA

Ligand: chemerin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.31 pKd
Reference (Journal): The genetic design of signaling cascades to record receptor activation.
Published in: Proc Natl Acad Sci USA

Ligand: chemerin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids.
Published in: J Exp Med

Ligand: chemerin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.010000228881836 pEC50
Reference (Journal): A novel CMKLR1 small molecule antagonist suppresses CNS autoimmune inflammatory disease.
Published in: PLoS ONE

Ligand: compound 14f [PMID: 35063894] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.920000076293945 pIC50
Reference (Journal): Discovery and mechanistic study of thiazole-4-acylsulfonamide derivatives as potent and orally active ChemR23 inhibitors with a long-acting effect in cynomolgus monkeys.
Published in: Bioorg Med Chem

Ligand: chemerin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Screening β-Arrestin Recruitment for the Identification of Natural Ligands for Orphan G-Protein-Coupled Receptors.
Published in: J Biomol Screen

Ligand: chemerin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency.
Published in: J Biol Chem

Ligand: chemerin C-terminal peptide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency.
Published in: J Biol Chem

Ligand: chemerin C-terminal peptide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): The genetic design of signaling cascades to record receptor activation.
Published in: Proc Natl Acad Sci USA